Biktarvy (Bictegravir / Emtricitabine / Tenofovir Alafenamide)

Biktarvy is a medicine used to treat HIV. It is one pill taken once a day that contains three HIV medicines. It works by stopping the virus from copying itself, which keeps the amount of virus in the body very low.

Brand names:Biktarvy
Medication

What people taking Biktarvy (Bictegravir / Emtricitabine / Tenofovir Alafenamide) report

Every report comes from a Lived member, sent anonymously.

Have you tried Biktarvy (Bictegravir / Emtricitabine / Tenofovir Alafenamide) for HIV Infection?

NameHow it went

About Biktarvy (Bictegravir / Emtricitabine / Tenofovir Alafenamide)

What It's For

Biktarvy is a prescription tablet that treats HIV-1, the most common type of HIV. Each tablet combines three HIV medicines: bictegravir, emtricitabine and tenofovir alafenamide. Because one tablet contains a complete treatment regimen, it is taken on its own rather than alongside other HIV medicines. It is approved for adults and children who weigh at least 14 kg (about 31 pounds) in three situations. The first is starting HIV treatment for the first time. The second is people who have taken HIV medicines before but whose virus is not currently controlled, as long as testing shows no resistance to its ingredients or to the drug class bictegravir belongs to. The third is switching from another regimen when the virus is already suppressed, meaning blood tests show fewer than 50 copies of HIV per milliliter. Expert HIV guidelines list regimens built on bictegravir or dolutegravir (a closely related HIV medicine) as recommended starting treatments for most people. CDC guidelines also name Biktarvy as a preferred option for post-exposure prophylaxis (PEP): a 28-day course started as soon as possible, and no later than 72 hours, after a possible exposure to HIV. This is a guideline recommendation rather than a labeled use. Biktarvy is not approved for daily HIV prevention (PrEP) in people who do not have HIV.

How It Works

HIV infects CD4 cells, the white blood cells that help coordinate the body's defense against infection. To multiply, the virus must first copy its genetic material into DNA and then insert that DNA into the cell's own genes. Biktarvy blocks both steps. Emtricitabine and tenofovir alafenamide are nucleoside reverse transcriptase inhibitors (NRTIs). Inside the cell they act as faulty building blocks: when the viral copying enzyme, reverse transcriptase, picks one up, the DNA chain it is building stops short. Bictegravir is an integrase inhibitor. It blocks integrase, the enzyme HIV uses to splice its DNA into the cell's genes, so the virus cannot set up the permanent foothold it needs to produce new copies. With fewer new copies being made, the amount of virus in the blood (the viral load) falls, and the immune system has a chance to rebuild its CD4 cells.

Dosage & Administration

Biktarvy is one tablet taken by mouth once a day, with or without food. Taking it at about the same time each day helps make it routine. Adults and children weighing at least 25 kg take the standard tablet; children from 14 kg to under 25 kg take a lower-strength tablet. A child who cannot swallow a whole tablet can have it split, as long as all the pieces are taken within about 10 minutes. People on regular hemodialysis who are eligible for Biktarvy take it after their dialysis session on dialysis days. Steady daily dosing matters more than with many medicines. Skipping doses, even for a short time, gives the virus room to multiply and can lead to resistance, which may make Biktarvy and related HIV medicines stop working. If a dose is missed, take it when remembered, but do not take two doses to make up for one. Refilling before the supply runs out is part of the plan, and Biktarvy should not be stopped without talking to the prescriber.

Side Effects

Most people tolerate Biktarvy well. In the main clinical trials, the most common side effects were diarrhea, nausea and headache, each reported by about 6% of people or fewer, and about 1% stopped the medicine because of side effects. Tiredness and unusual dreams were less common. Blood tests often show a small rise in creatinine, a waste product used to estimate kidney function. Bictegravir causes this by slowing how the kidneys release creatinine into urine, not by damaging the kidneys, and the change usually appears within the first month and then stays stable. Genuine kidney problems are uncommon but have been reported, particularly in people with existing kidney disease or who also take kidney-straining medicines such as regular or high-dose anti-inflammatory pain relievers like ibuprofen or naproxen. Rarely, medicines in the NRTI family have caused lactic acidosis (a dangerous buildup of acid in the blood) or severe liver enlargement. Contact the prescriber right away, or get emergency care if symptoms are severe, for unusual muscle pain or weakness, fast or difficult breathing, stomach pain with nausea and vomiting, cold or bluish hands and feet, or a fast or irregular heartbeat. Yellowing of the skin or eyes, dark urine, light-colored stools, noticeably less urination or new swelling of the feet and ankles also need a prompt call. In the first weeks of treatment, especially for someone whose immune system was badly weakened, the recovering immune system can start reacting to an infection that was already present but quiet. This is called immune reconstitution syndrome. New fever or other signs of infection after starting should be reported to the care team promptly.

Interactions & Warnings

Biktarvy carries an FDA boxed warning, the agency's most prominent kind, about hepatitis B. In people who have both HIV and hepatitis B, stopping Biktarvy can cause a severe flare of hepatitis B that can lead to liver failure. For this reason everyone is tested for hepatitis B before starting. Anyone with hepatitis B should not stop or interrupt Biktarvy without a plan from the prescriber, which includes liver checks for at least several months afterward and, when appropriate, a separate hepatitis B treatment. Two medicines must not be taken with Biktarvy: dofetilide, a heart rhythm medicine that Biktarvy can push to dangerous levels, and rifampin, a tuberculosis antibiotic that lowers bictegravir levels enough for treatment to fail and resistance to develop. Other medicines that lower Biktarvy levels and are not recommended with it include the tuberculosis antibiotics rifabutin and rifapentine and the herbal supplement St. John's wort. The seizure medicines carbamazepine, oxcarbazepine, phenobarbital and phenytoin have a similar effect, so a different seizure medicine is usually considered. Biktarvy also raises levels of metformin, a common diabetes medicine, so that combination should be reviewed. Antacids and mineral supplements can reduce how much bictegravir the body absorbs. Take Biktarvy at least 2 hours before or 6 hours after antacids containing aluminum or magnesium. Calcium or iron supplements, and antacids containing them, can be taken at the same time as Biktarvy with food, but not together on an empty stomach. Because the list of interactions is long, the prescriber and pharmacist should review every prescription, over-the-counter medicine and supplement before starting and whenever something new is added. Biktarvy is not recommended for people with severe liver impairment or severe kidney impairment, except for certain people whose virus is already suppressed and who are on regular hemodialysis. People whose virus is already suppressed can stay on Biktarvy during pregnancy. Drug levels run lower in pregnancy, so viral load is checked more closely. Pregnancy registry data have not shown an increased risk of birth defects. HIV can pass to a baby through breastfeeding, so infant feeding is worth planning with the care team.

What to Expect

HIV treatment is recommended for everyone with HIV and usually starts soon after diagnosis. Viral load tests show how well it is working. Most people who take HIV medicine as prescribed reach an undetectable viral load, meaning a standard lab test can no longer find the virus in the blood, within about six months. In the main trials of people starting treatment, about 82% had fewer than 50 copies per milliliter after nearly three years on Biktarvy, similar to the comparison regimens. The CD4 count, a measure of immune strength, typically rises over the same period. Biktarvy does not cure HIV. The virus remains in the body even when it is undetectable, and if doses are skipped the viral load can climb quickly. Treatment therefore continues long term, although the specific regimen can be changed because of side effects, interactions, convenience or cost. Keeping the viral load undetectable lets people with HIV live long, healthy lives, and it means they will not pass HIV to partners through sex, often summarized as undetectable equals untransmittable (U=U). Ongoing care includes regular viral load tests and periodic blood and urine checks of kidney function. An occasional low-level detectable result, called a blip, does not necessarily mean treatment has stopped working, but it is worth reviewing with the care team, as is any trouble taking doses every day.

Questions to Ask Your Doctor

  1. 1.Have I been tested for hepatitis B, and how would the result change what happens if I ever stop or switch Biktarvy?
  2. 2.Which of my other medicines, antacids or supplements need to be changed or timed differently around my dose?
  3. 3.What should I do if I miss a dose, or if I am about to run out while traveling?
  4. 4.How often will my viral load and kidney tests be checked, and what results would lead us to change treatment?
  5. 5.If I become pregnant or plan to, should I stay on Biktarvy, and what extra monitoring would I need?

Last reviewed • Oct 2026

Educational content, not medical advice.